[1] Akateh C, Ejaz AM, Pawlik TM, et al, Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma[J]. World J Hepatol, 2020,12(10):693-708. [2] Khan AS, Dageforde LA, Cholangiocarcinoma[J]. Surg Clin North Am, 2019,99(2):315-335. [3] Massarweh NN, El-Serag HB, Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Cancer Controll, 2017,24(3):1073274817729245. [4] Blechacz B, Komuta M,Roskams T, alet, Clinical diagnosis and staging of cholangiocarcinoma[J]. Nat Rev Gastroenterol Hepatol,2011,8(9):512-522. [5] Thorsen MK, Quiroz F, Lawson TL, et al.Primary biliary carcinoma: CT evaluation[J]. Radiology, 1984,152(2):479-483. [6] Yang XQ, Xu YF, Guo S, et al.Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma[J]. WJG, 2014,20(14):4076-4084. [7] Ariizumi S, Kotera Y, Katagiri S, et al.Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy[J]. Ann Surg Oncol, 2014,21(Suppl 3):451-458. [8] Luo X, Yuan L, Wang Y, et al.Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study[J]. J Gastrointest Surg, 2014,18(3):562-572. [9] He CB,Zhang Y, Song Y, et al.Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma[J]. Cancer, 2018,9(17):3117-3128. [10] Rangaraj A,Ye L, Sanders AJ, et al.Molecular and cellular impact of psoriasin (S100A7) on the healing of human wounds[J]. Exp Ther Med,2017,13(5):2151-2160. [11] Donato R.S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles[J]. Int J Biochem Cell Biol, 2001,33(7):637-668. [12] De Cid R, Riveira-Munoz E, Zeeuwen Patrick LJM, et al.Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis[J]. Nat Gene ,2009,41(2):211-215. [13] Bresnick AR.S100 proteins as therapeutic targets[J]. Biophys Rev, 2018,10(6):1617-1629. [14] Brodersen DE, Nyborg J, Kjeldgaard M.Zinc-binding site of an S100 protein revealed. Two crystal structures of Ca2+-bound human psoriasin (S100A7) in the Zn2+-loaded and Zn2+-free states[J]. Biochemistry, 1999,38(6):1695-1704. [15] Fan JJ, Hsu WH, Lee KH,et al.Dietary flavonoids luteolin and quercetin inhibit migration and invasion of squamous carcinoma through reduction of Src/Stat3/S100A7 signaling[J]. Antioxidants (Basel), 2019,8(11):557. [16] Tian T,Li XK,Hua Z, et al.S100A7 promotes the migration, invasion and metastasis of human cervical cancer cells through epithelial-mesenchymal transition[J]. Oncotarget, 2017,8(15):24964-24977. [17] Sakurai M, Miki Y, Takagi K, et al.Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment[J]. Breast Cancer Res,2017,19(1):70. [18] Wang R, Li YG, Hu Enze HU, et al.S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells[J]. Oncotarget, 2017,8(15):24804-24814. [19] Sneh A, Deol YS, Ganju A, et al.Differential role of psoriasin (S100A7) in estrogen receptor alpha positive and negative breast cancer cells occur through actin remodeling[J]. Breast Cancer Res Treat, 2013,138(3):727-739. [20] Deol YS, Nasser MW, Yu L, et al.Tumor-suppressive effects of psoriasin (S100A7) are mediated through the beta-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells[J]. J Biol Chem, 2011,286(52):44845-44854. [21] Fan F, Lu JJ, Yu WL,et al.MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7[J]. Oncol Lett,2018,15(1):386-392. |